Neuropace Inc (NPCE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neuropace Inc stock (NPCE) is currently trading at $13.53. Neuropace Inc PS ratio (Price-to-Sales) is 4.50. Analyst consensus price target for NPCE is $19.88. WallStSmart rates NPCE as Sell.
- NPCE PE ratio analysis and historical PE chart
- NPCE PS ratio (Price-to-Sales) history and trend
- NPCE intrinsic value — DCF, Graham Number, EPV models
- NPCE stock price prediction 2025 2026 2027 2028 2029 2030
- NPCE fair value vs current price
- NPCE insider transactions and insider buying
- Is NPCE undervalued or overvalued?
- Neuropace Inc financial analysis — revenue, earnings, cash flow
- NPCE Piotroski F-Score and Altman Z-Score
- NPCE analyst price target and Smart Rating
Neuropace Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Neuropace Inc (NPCE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Neuropace Inc (NPCE) Key Strengths (2)
95.00% of shares held by major funds and institutions
Strong revenue growth at 23.90% annually
Supporting Valuation Data
Neuropace Inc (NPCE) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 23.7x book value
Premium valuation at 4.5x annual revenue
Small-cap company with higher risk but more growth potential
Neuropace Inc (NPCE) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth. Growth metrics are encouraging with Revenue Growth at 23.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (4.50), Price/Book (23.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -158.70%, Operating Margin at -6.65%, Profit Margin at -21.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -158.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 23.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NPCE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NPCE's Price-to-Sales ratio of 4.50x trades 27% below its historical average of 6.13x (41th percentile). The current valuation is 77% below its historical high of 19.56x set in Apr 2021, and 310% above its historical low of 1.1x in Dec 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neuropace Inc (NPCE) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Neuropace Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 100M with 24% growth year-over-year. The company is currently unprofitable, posting a -21.5% profit margin.
Key Findings
Generating 409,000 in free cash flow and 506,000 in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -21.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Neuropace Inc maintain 24%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.86, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Neuropace Inc.
Bottom Line
Neuropace Inc offers an attractive blend of growth (24% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(7 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MORRELL, MARTHA CHIEF MEDICAL OFFICER | Sell | -3,412 |
Data sourced from SEC Form 4 filings
Last updated: 8:22:17 AM
About Neuropace Inc(NPCE)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.